Henry Schein, Inc. (NASDAQ:HSIC) – Equities researchers at Barrington Research lowered their Q4 2017 earnings estimates for shares of Henry Schein in a research note issued on Wednesday. Barrington Research analyst M. Petusky now anticipates that the company will earn $1.99 per share for the quarter, down from their prior forecast of $2.03. Barrington Research has a “Outperform” rating and a $198.00 price objective on the stock. Barrington Research also issued estimates for Henry Schein’s Q3 2018 earnings at $1.98 EPS.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, August 8th. The company reported $1.75 EPS for the quarter, topping the Zacks’ consensus estimate of $1.73 by $0.02. The company had revenue of $3.06 billion for the quarter, compared to analyst estimates of $3.05 billion. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. Henry Schein’s revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.64 earnings per share.

TRADEMARK VIOLATION WARNING: “Henry Schein, Inc. (NASDAQ:HSIC) to Post Q4 2017 Earnings of $1.99 Per Share, Barrington Research Forecasts” was posted by Daily Political and is owned by of Daily Political. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/10/henry-schein-inc-nasdaqhsic-to-post-q4-2017-earnings-of-1-99-per-share-barrington-research-forecasts.html.

Other equities research analysts also recently issued research reports about the company. Jefferies Group LLC restated a “hold” rating and set a $177.00 target price on shares of Henry Schein in a research report on Friday, July 21st. Zacks Investment Research downgraded Henry Schein from a “buy” rating to a “hold” rating in a research report on Wednesday. Stifel Nicolaus reiterated a “hold” rating on shares of Henry Schein in a research report on Thursday, July 6th. BidaskClub downgraded Henry Schein from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Finally, Northcoast Research upgraded Henry Schein from a “neutral” rating to a “buy” rating and set a $218.00 price objective on the stock in a research report on Monday. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $185.56.

Henry Schein (NASDAQ HSIC) traded down 1.80% during midday trading on Thursday, hitting $166.60. The stock had a trading volume of 133,573 shares. The stock has a market capitalization of $13.19 billion, a price-to-earnings ratio of 24.35 and a beta of 1.09. The company’s 50 day moving average price is $182.39 and its 200-day moving average price is $175.07. Henry Schein has a 52 week low of $146.23 and a 52 week high of $186.99.

Large investors have recently added to or reduced their stakes in the stock. SpiderRock Advisors LLC purchased a new stake in Henry Schein during the first quarter worth $102,000. Lee Financial Co purchased a new stake in Henry Schein during the second quarter worth $161,000. Westside Investment Management Inc. purchased a new stake in Henry Schein during the first quarter worth $168,000. JNBA Financial Advisors purchased a new stake in Henry Schein during the first quarter worth $170,000. Finally, Peddock Capital Advisors LLC increased its stake in Henry Schein by 29.1% in the first quarter. Peddock Capital Advisors LLC now owns 1,097 shares of the company’s stock worth $186,000 after buying an additional 247 shares during the last quarter. Institutional investors and hedge funds own 90.87% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.